RecruitingPhase 1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

142

Study population

Obesity / overweight

Eligibility highlights

•BMI 27-34.9

Primary endpoints

•Part•Part B•Part C

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07767175

Org study IDNN9060-8607

Secondary IDU1111-1334-3077Universal Trial Number

Timeline

Milestones

Study start2026-08-12actual

Study first posted2026-08-17actual

Last update posted2026-09-04actual

Primary completion2027-09-23estimated

Study completion2027-09-23estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Male or female (sex at birth).

•Age 18-55 years (both inclusive) at the time of signing informed consent.

•Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.

•Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.

Exclusion criteria

•Known or suspected hypersensitivity to study intervention(s) or related products.

•Previous randomisation in this study.

•History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.

•Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.

•Current participation (signed informed consent) in any other interventional clinical study.

•Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.

•Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.

•Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole [mmol/mol]) at screening.

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

1 endpoint

Primary/protocol endpoint

Part C: Change from baseline in body weight

Time frame:From Day 1 to Day 85

change from baseline, improvement

Safety / tolerability / PK

9 endpoints

Primary/protocol endpoint

Part A: Number of treatment emergent adverse events (TEAE)

Time frame:From Day 1 to Day 36

event count, event

Primary/protocol endpoint

Part B: Number of treatment emergent adverse events (TEAE)

Time frame:From Day 1 to Day 57

event count, event

Secondary/protocol endpoint

Part A: AUC- Area under the NNC0721-8060 plasma concentration time-curve

Time frame:From Day 1 to Day 36

concentration, descriptive

Secondary/protocol endpoint

Part A: Cmax- Maximum observed plasma concentration of NNC0721-8060

Time frame:From Day 1 to Day 36

concentration, descriptive

Secondary/protocol endpoint

Part B: AUC- Area under the NNC0721-8060 plasma concentration time-curve

Time frame:From Day 1 to Day 57

concentration, descriptive

Secondary/protocol endpoint

Part B: Cmax- Maximum observed plasma concentration of NNC0721-8060

Time frame:From Day 1 to Day 57

concentration, descriptive

Secondary/protocol endpoint

Part C: AUC- Area under the NNC0721-8060 plasma concentration time-curve

Time frame:From Day 1 to Day 113

concentration, descriptive

Secondary/protocol endpoint

Part C: Cmax- Maximum observed plasma concentration of NNC0721-8060

Time frame:From Day 1 to Day 113

concentration, descriptive

Secondary/protocol endpoint

Part C: Number of treatment emergent adverse events (TEAE)

Time frame:From Day 1 to Day 113

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.